Даваа–Баасан 08:30–20:00 · Бямба 09:00–16:00

АШУҮИС — Судалгааны мэдээлэл (CRIS)

Permanent URI for this communityhttps://library.mnums.edu.mn/handle/123456789/5001

Browse

Search Results

Now showing 1 - 3 of 3
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Additional file 1 of Factors associated with severe pneumonia in adults hospitalised with community-acquired pneumonia in Mongolia
    (Figshare (United Kingdom), 2026-01-01)
    Amy Simkiss
    ;
    Munkhchuluun Ulziibayar
    ;
    Purevsuren Batsaikhan
    ;
    Bujinlkham Suuri
    ;
    Dashtseren Luvsantseren
    Supplementary Material 1: Supplementary Table 1. Describes demographic characteristics and risk factors with multiple categories in adults hospitalised with clinical community acquired pneumonia by severity status. The data in this table expands upon the binary categories used for these variables in Table 1.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Additional file 1 of Factors associated with severe pneumonia in adults hospitalised with community-acquired pneumonia in Mongolia
    (Figshare (United Kingdom), 2026-01-01)
    Amy Simkiss
    ;
    Munkhchuluun Ulziibayar
    ;
    Purevsuren Batsaikhan
    ;
    Bujinlkham Suuri
    ;
    Dashtseren Luvsantseren
    Supplementary Material 1: Supplementary Table 1. Describes demographic characteristics and risk factors with multiple categories in adults hospitalised with clinical community acquired pneumonia by severity status. The data in this table expands upon the binary categories used for these variables in Table 1.
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Effect of Pneumococcal Conjugate Vaccine on Pneumonia Incidence Rates among Children 2–59 Months of Age, Mongolia, 2015–2021
    (Centers for Disease Control and Prevention, 2024-02-23)
    Claire von Mollendorf
    ;
    Munkhchuluun Ulziibayar
    ;
    Cattram Duong Nguyen
    ;
    Purevsuren Batsaikhan
    ;
    Bujinlkham Suuri
    Starting in June 2016, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced into the routine immunization program of Mongolia by using a 2+1 dosing schedule, phased by district. We used prospective hospital surveillance to evaluate the vaccine's effect on pneumonia incidence rates among children 2-59 months of age over a 6-year period. Of 17,607 children with pneumonia, overall adjusted incidence rate ratios showed decreased primary endpoint pneumonia, very severe pneumonia, and probable pneumococcal pneumonia until June 2021. Results excluding and including the COVID-19 pandemic period were similar. Pneumonia declined in 3 districts that introduced PCV13 with catch-up campaigns but not in the 1 district that did not. After PCV13 introduction, vaccine-type pneumococcal carriage prevalence decreased by 44% and nonvaccine-type carriage increased by 49%. After PCV13 introduction in Mongolia, the incidence of more specific pneumonia endpoints declined in children 2-59 months of age; additional benefits were conferred by catch-up campaigns.
    Scopus© Citations 11